董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Wills | 男 | Director | 68 | 14.28万美元 | 未持股 | 2022-02-28 |
| Caroline Loewy | -- | Director | -- | 未披露 | 未持股 | 2022-02-28 |
| Thomas G. Wiggans | -- | Director | -- | 未披露 | 未持股 | 2022-02-28 |
| Janet Dorling | -- | Director | -- | 未披露 | 未持股 | 2022-02-28 |
| Sujal Shah | 男 | President & Chief Executive Officer,Director | 48 | 110.75万美元 | 未持股 | 2022-02-28 |
| Kurt von Emster | 男 | Director, CFA | 54 | 12.38万美元 | 未持股 | 2022-02-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Klara Dickinson | 女 | Chief Regulatory and Quality Assurance Officer | 55 | 未披露 | 未持股 | 2022-02-28 |
| Daniel Menold | 男 | Vice President, Finance | 52 | 未披露 | 未持股 | 2022-02-28 |
| Dennis Kim | 男 | Chief Medical Officer, Vice President, Finance | 52 | 未披露 | 未持股 | 2022-02-28 |
| Lewis Stuart | 男 | Chief Commercial Officer | 62 | 未披露 | 未持股 | 2022-02-28 |
| Paul T. Quinlan | 男 | General Counsel and Chief Compliance Officer | 59 | 未披露 | 未持股 | 2022-02-28 |
| Sujal Shah | 男 | President & Chief Executive Officer,Director | 48 | 110.75万美元 | 未持股 | 2022-02-28 |
| Charles A. McWherter | 男 | Chief Scientific Officer | 67 | 112.42万美元 | 未持股 | 2022-02-28 |
| Kurt von Emster | 男 | Director, CFA | 54 | 12.38万美元 | 未持股 | 2022-02-28 |
董事简历
中英对照 | 中文 | 英文- Robert J. Wills
-
Robert J. Wills，于2015年3月加入Oncternal Therapeutics, Inc.董事会担任执行主席，并自2019年6月合并完成以来一直担任Oncternal Therapeutics, Inc.董事会成员。Wills还担任CymaBay Therapeutics的董事会主席、Milestone Pharmaceuticals的董事会主席、Parion Sciences的董事会成员、Go Therapeutics的董事会成员和Feldan Therapeutics的董事会成员。在担任这些职务之前，他在Johnson & Johnson公司工作了超过25年。最近，他担任Johnson & Johnson的Janssen Pharmaceutical Companies的联盟管理副总裁。他还担任全球发展高级副总裁，负责研发管道和研发董事会成员。此外，他曾在几个商业运营公司董事会和关键制药集团决策委员会任职。他在Hoffmann-LaRoche开始了他的职业生涯，在那里他花了10年时间担任多个科学责任角色。他持有the University of Wisconsin的生物化学学士学位和药剂学硕士学位，以及the University of Texas的药剂学博士学位。
Robert J. Wills,joined Oncternal Therapeutics, Inc. board as the Executive Chairman in March 2015, and has served as a member of Oncternal Therapeutics, Inc. board since the completion of the Merger in June 2019.Dr. Wills also serves as Chairman of the Board of CymaBay Therapeutics, as Chairman of the Board at Milestone Pharmaceuticals, Inc., as board member at Parion Sciences, Inc., as board member at Go Therapeutics and as a board member of Feldan Therapeutics. Prior to these roles, Dr. Wills spent over 25 years at Johnson & Johnson. Most recently he was Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson. He also served as Senior Vice President Global Development, where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition, he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr. Wills began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility. He holds a BS in Biochemistry and an MS in Pharmaceutics from the University of Wisconsin and a PhD in Pharmaceutics from the University of Texas. - Robert J. Wills，于2015年3月加入Oncternal Therapeutics, Inc.董事会担任执行主席，并自2019年6月合并完成以来一直担任Oncternal Therapeutics, Inc.董事会成员。Wills还担任CymaBay Therapeutics的董事会主席、Milestone Pharmaceuticals的董事会主席、Parion Sciences的董事会成员、Go Therapeutics的董事会成员和Feldan Therapeutics的董事会成员。在担任这些职务之前，他在Johnson & Johnson公司工作了超过25年。最近，他担任Johnson & Johnson的Janssen Pharmaceutical Companies的联盟管理副总裁。他还担任全球发展高级副总裁，负责研发管道和研发董事会成员。此外，他曾在几个商业运营公司董事会和关键制药集团决策委员会任职。他在Hoffmann-LaRoche开始了他的职业生涯，在那里他花了10年时间担任多个科学责任角色。他持有the University of Wisconsin的生物化学学士学位和药剂学硕士学位，以及the University of Texas的药剂学博士学位。
- Robert J. Wills,joined Oncternal Therapeutics, Inc. board as the Executive Chairman in March 2015, and has served as a member of Oncternal Therapeutics, Inc. board since the completion of the Merger in June 2019.Dr. Wills also serves as Chairman of the Board of CymaBay Therapeutics, as Chairman of the Board at Milestone Pharmaceuticals, Inc., as board member at Parion Sciences, Inc., as board member at Go Therapeutics and as a board member of Feldan Therapeutics. Prior to these roles, Dr. Wills spent over 25 years at Johnson & Johnson. Most recently he was Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson. He also served as Senior Vice President Global Development, where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition, he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr. Wills began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility. He holds a BS in Biochemistry and an MS in Pharmaceutics from the University of Wisconsin and a PhD in Pharmaceutics from the University of Texas.
- Caroline Loewy
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Thomas G. Wiggans
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Janet Dorling
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Sujal Shah
-
Sujal Shah于2013年12月加入CymaBay，担任财务总监。在此之前，自2012年6月以来曾担任顾问和代理首席财务官。自2010年至2012年担任花旗集团卫生保健投资银行业务的主任，负责管理客户关系，并执行战略和融资相关交易，为专注于生命科学领域的客户服务。从2004年至2010年受雇于Credit-Suisse，最后担任医疗保健投资银行集团的副总裁。2004年在卡耐基梅隆大学泰珀商学院收到了工商管理硕士学位，1997年在美国西北大学获得生物医学工程学士学位。
Sujal Shah has served as our President and Chief Executive Officer since November 2017. Prior to that he served as our Interim President and Chief Executive Officer from March 2017 to November 2017. From December 2013 to March 2017 Mr. Shah served as Chief Financial Officer. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012 Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Directors of Tvardi Therapeutics, Inc. and the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received an M.B.A. from Carnegie Mellon University-Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University. - Sujal Shah于2013年12月加入CymaBay，担任财务总监。在此之前，自2012年6月以来曾担任顾问和代理首席财务官。自2010年至2012年担任花旗集团卫生保健投资银行业务的主任，负责管理客户关系，并执行战略和融资相关交易，为专注于生命科学领域的客户服务。从2004年至2010年受雇于Credit-Suisse，最后担任医疗保健投资银行集团的副总裁。2004年在卡耐基梅隆大学泰珀商学院收到了工商管理硕士学位，1997年在美国西北大学获得生物医学工程学士学位。
- Sujal Shah has served as our President and Chief Executive Officer since November 2017. Prior to that he served as our Interim President and Chief Executive Officer from March 2017 to November 2017. From December 2013 to March 2017 Mr. Shah served as Chief Financial Officer. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012 Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Directors of Tvardi Therapeutics, Inc. and the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received an M.B.A. from Carnegie Mellon University-Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.
- Kurt von Emster
-
Kurt von Emster，终审法院，自2009年4月起担任董事。由于他对医药行业的深入了解和他对MPM BioEquities Master Fund LP的投资，被选为董事会成员。他是venBio LLC的创办人之一和管理合伙人。23年来一直担任生物技术和医疗保健分析师和投资组合经理。他是Aurinia制药公司和Cytos Biotechnology AG的董事，曾任Facet Biotech公司（在2010年出售给雅培公司）和SOMAXON制药公司（在2013年卖给Pernix治疗控股有限公司）的董事会前成员，和Acceleron制药公司的前董事会观察员。他的投资生涯开始于1989年在富兰克林邓普顿的投资，在20世纪90年代创立并管理各种健康和生物技术基金会，每个基金会实现一个5星级的晨星排名。 2000年，他为Franklin Templeton管理超过20亿美元的生物技术和医疗保健基金。 2001年，他成为MPM Capital（一家领先的生物技术私募股权公司）的普通合伙人，并推出了MPM BioEquities基金（一个跨越公共和私营生物技术的对冲基金）。从2001年成立直到2009年离开，他是这个基金的投资组合经理。在MPM的任职期间，他还与他人共同创办了MPM Biogen Idec公司战略基金。他在venBio的旧金山办公室工作。
Kurt von Emster has served on our board of directors since October 2020. Mr. von Emster currently serves as Managing Partner at Abingworth LLP, a venture capital firm, where he has been employed as a Partner since January 2015. Mr. von Emster has served as a member of the board of directors of Tizona Therapeutics, Inc, a biotechnology company, since December 2020 Trishula Therapeutics, Inc., an immunotherapy company, since December 2020 Orbus Therapeutics, Inc., a pharmaceutical company, since July 2020 SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since April 2020 Jasper Therapeutics, Inc., a biotechnology company, since November 2019 Vaxcyte Inc. Vaxcyte, a biopharmaceutical vaccine company, since July 2015 and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr. von Emster previously served on the board of directors of the following companies: CRISPR Therapeutics, Inc. from March 2015 to June 2019 Kesios Therapeutics Ltd. from November 2015 to January 2017 Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros Biosciences AG in January 2016), Aurinia Pharmaceuticals Inc. from February 2014 to March 2015 Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from February 2009 to April 2010 and Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics Holdings, Inc. in March 2013) from August 2005 to March 2013. In addition, Mr. von Emster co-founded venBio LLC, a health-care focused investment firm, in 2009 and served as Partner until 2014. Prior to that, Mr. von Emster was General Partner at MPM Capital, Inc., a biotechnology private equity firm, from 2000 to 2009. Mr. von Emster was also a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton Group from 1989 to 2000. Mr. von Emster received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (C.F.A.). - Kurt von Emster，终审法院，自2009年4月起担任董事。由于他对医药行业的深入了解和他对MPM BioEquities Master Fund LP的投资，被选为董事会成员。他是venBio LLC的创办人之一和管理合伙人。23年来一直担任生物技术和医疗保健分析师和投资组合经理。他是Aurinia制药公司和Cytos Biotechnology AG的董事，曾任Facet Biotech公司（在2010年出售给雅培公司）和SOMAXON制药公司（在2013年卖给Pernix治疗控股有限公司）的董事会前成员，和Acceleron制药公司的前董事会观察员。他的投资生涯开始于1989年在富兰克林邓普顿的投资，在20世纪90年代创立并管理各种健康和生物技术基金会，每个基金会实现一个5星级的晨星排名。 2000年，他为Franklin Templeton管理超过20亿美元的生物技术和医疗保健基金。 2001年，他成为MPM Capital（一家领先的生物技术私募股权公司）的普通合伙人，并推出了MPM BioEquities基金（一个跨越公共和私营生物技术的对冲基金）。从2001年成立直到2009年离开，他是这个基金的投资组合经理。在MPM的任职期间，他还与他人共同创办了MPM Biogen Idec公司战略基金。他在venBio的旧金山办公室工作。
- Kurt von Emster has served on our board of directors since October 2020. Mr. von Emster currently serves as Managing Partner at Abingworth LLP, a venture capital firm, where he has been employed as a Partner since January 2015. Mr. von Emster has served as a member of the board of directors of Tizona Therapeutics, Inc, a biotechnology company, since December 2020 Trishula Therapeutics, Inc., an immunotherapy company, since December 2020 Orbus Therapeutics, Inc., a pharmaceutical company, since July 2020 SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since April 2020 Jasper Therapeutics, Inc., a biotechnology company, since November 2019 Vaxcyte Inc. Vaxcyte, a biopharmaceutical vaccine company, since July 2015 and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr. von Emster previously served on the board of directors of the following companies: CRISPR Therapeutics, Inc. from March 2015 to June 2019 Kesios Therapeutics Ltd. from November 2015 to January 2017 Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros Biosciences AG in January 2016), Aurinia Pharmaceuticals Inc. from February 2014 to March 2015 Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from February 2009 to April 2010 and Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics Holdings, Inc. in March 2013) from August 2005 to March 2013. In addition, Mr. von Emster co-founded venBio LLC, a health-care focused investment firm, in 2009 and served as Partner until 2014. Prior to that, Mr. von Emster was General Partner at MPM Capital, Inc., a biotechnology private equity firm, from 2000 to 2009. Mr. von Emster was also a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton Group from 1989 to 2000. Mr. von Emster received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (C.F.A.).
高管简历
中英对照 | 中文 | 英文- Klara Dickinson
Klara Dickinson自2019年1月起担任我们的首席监管和合规官，此前曾担任我们的监管事务和合规高级副总裁。在2017年6月加入Cymabay之前，她曾担任Anthera的高级副总裁，首席监管官。从2007年到2014年，她担任Hyperion Therapeutics Inc.的监管事务和合规高级副总裁。Dickinson女士还在Cotherix，Inc.担任了三年的Vice President、法规事务和梦百合合规官，并在生物制药公司Scios，Inc.和Mylan，Inc.的子公司Dey Laboratories担任过多个职位。Dickinson女士拥有蒙大拿州大瀑布学院（College of Great Falls）的生物学学士学位，并获得监管事务认证委员会（Regulatory Affairs Certification Board）认证。
Klara Dickinson has served as our Chief Regulatory and Quality Assurance Officer since October 2020. Prior to that she was our Chief Regulatory and Compliance Officer since January 2019 and our Senior Vice President, Regulatory Affairs and Compliance since June 2017. Previously, she served as Senior Vice President, Chief Regulatory Officer of Anthera Pharmaceuticals, Inc., a biopharmaceutical company. From 2007 to 2014 she was Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc, where she was responsible for the general supervision of the company's regulatory affairs and quality assurance. Ms. Dickinson also spent three years at CoTherix, Inc. as Vice President, Regulatory Affairs and Healthcare Compliance Officer, and held various positions at biopharmaceutical companies such as Scios, Inc. and DEY Laboratories a subsidiary of Mylan, Inc.. Ms. Dickinson holds a B.S. in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.- Klara Dickinson自2019年1月起担任我们的首席监管和合规官，此前曾担任我们的监管事务和合规高级副总裁。在2017年6月加入Cymabay之前，她曾担任Anthera的高级副总裁，首席监管官。从2007年到2014年，她担任Hyperion Therapeutics Inc.的监管事务和合规高级副总裁。Dickinson女士还在Cotherix，Inc.担任了三年的Vice President、法规事务和梦百合合规官，并在生物制药公司Scios，Inc.和Mylan，Inc.的子公司Dey Laboratories担任过多个职位。Dickinson女士拥有蒙大拿州大瀑布学院（College of Great Falls）的生物学学士学位，并获得监管事务认证委员会（Regulatory Affairs Certification Board）认证。
- Klara Dickinson has served as our Chief Regulatory and Quality Assurance Officer since October 2020. Prior to that she was our Chief Regulatory and Compliance Officer since January 2019 and our Senior Vice President, Regulatory Affairs and Compliance since June 2017. Previously, she served as Senior Vice President, Chief Regulatory Officer of Anthera Pharmaceuticals, Inc., a biopharmaceutical company. From 2007 to 2014 she was Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc, where she was responsible for the general supervision of the company's regulatory affairs and quality assurance. Ms. Dickinson also spent three years at CoTherix, Inc. as Vice President, Regulatory Affairs and Healthcare Compliance Officer, and held various positions at biopharmaceutical companies such as Scios, Inc. and DEY Laboratories a subsidiary of Mylan, Inc.. Ms. Dickinson holds a B.S. in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.
- Daniel Menold
Daniel Menold自2017年4月起担任公司财务Vice President，此前自2014年1月起担任公司财务总监。在加入Cymabay之前，Menold先生于2011年至2013年担任技术公司Zoosk，Inc.的公司财务总监，在那里他负责会计和财务报告职能，并担任Affymetrix的财务总监兼会计总监。2005年之前，他也曾担任硅谷公共和私人生命科学和高科技公司的会计和财务职务，并承担越来越大的责任。职业生涯早期，他曾任职Ernst&Young公司，在那里他曾担任审计经理，也曾任职生命科学和高科技公司的审计。Menold先生在弗吉尼亚大学麦金泰尔商学院（University of Virginia McIntire School of Commerce）获得会计学硕士学位和金融学学士学位。
Daniel Menold has served as our Vice President, Finance since April 2017 and previously served as our Corporate Controller since January 2014. Prior to joining CymaBay, Mr. Menold served as Corporate Controller for technology firm Zoosk, Inc., from 2011 to 2013 where he was responsible for the accounting and financial reporting functions and as Controller and Director of Accounting at Affymetrix, Inc. from 2005 to 2010. Prior to 2005 he also held accounting and finance positions of increasing responsibility at public and private life sciences and high technology companies in the Silicon Valley. Earlier in his career, Mr. Menold was at Ernst & Young LLP where he was an audit manager and served on audits of life sciences and high technology companies. Mr. Menold received a M.S. in accounting and B.S. in finance from The University of Virginia McIntire School of Commerce.- Daniel Menold自2017年4月起担任公司财务Vice President，此前自2014年1月起担任公司财务总监。在加入Cymabay之前，Menold先生于2011年至2013年担任技术公司Zoosk，Inc.的公司财务总监，在那里他负责会计和财务报告职能，并担任Affymetrix的财务总监兼会计总监。2005年之前，他也曾担任硅谷公共和私人生命科学和高科技公司的会计和财务职务，并承担越来越大的责任。职业生涯早期，他曾任职Ernst&Young公司，在那里他曾担任审计经理，也曾任职生命科学和高科技公司的审计。Menold先生在弗吉尼亚大学麦金泰尔商学院（University of Virginia McIntire School of Commerce）获得会计学硕士学位和金融学学士学位。
- Daniel Menold has served as our Vice President, Finance since April 2017 and previously served as our Corporate Controller since January 2014. Prior to joining CymaBay, Mr. Menold served as Corporate Controller for technology firm Zoosk, Inc., from 2011 to 2013 where he was responsible for the accounting and financial reporting functions and as Controller and Director of Accounting at Affymetrix, Inc. from 2005 to 2010. Prior to 2005 he also held accounting and finance positions of increasing responsibility at public and private life sciences and high technology companies in the Silicon Valley. Earlier in his career, Mr. Menold was at Ernst & Young LLP where he was an audit manager and served on audits of life sciences and high technology companies. Mr. Menold received a M.S. in accounting and B.S. in finance from The University of Virginia McIntire School of Commerce.
- Dennis Kim
Dennis KIM自2021年5月起担任我们的首席医疗官。从2020年11月至2021年3月，他担任局部药物输送公司Afyx Therapeutics的首席医疗官，在那里他领导了Rivelin的临床，医学和法规开发，Rivelin是一种新型黏膜粘合剂贴片，用于治疗口腔扁平苔藓等疾病。在此之前，从2019年3月至2020年11月，他担任生物技术公司Emerald Health Sciences的首席医疗官，负责公司临床和医疗事务的总体监督，从2011年9月至2019年2月，他担任生物技术公司Zafgen，Inc.的首席医疗官，负责公司临床和医疗事务的总体监督。在此之前，KIM博士在Orexigen，Enteromedics和Amylin Pharmaceutical担任高级领导职务。他获得了芝加哥医学院的医学学位，在拉什大学医学院完成了内科住院医师，并在加州大学圣地亚哥分校医学中心完成了内分泌学/新陈代谢的专业研究金培训。他还拥有UCSD Rady商学院的工商管理硕士学位，重点是生物技术结构和战略。
Dennis Kim has served as our Chief Medical Officer since May 2021. From November 2020 to March 2021 he served as Chief Medical Officer of Afyx Therapeutics, a topical drug delivery company, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus. Prior to this, from March 2019 to November 2020 he served as Chief Medical Officer of Emerald Health Sciences, a biotechnology company, where he was responsible for the general supervision of the company's clinical and medical affairs, and from September 2011 to February 2019 was Chief Medical Officer at Zafgen, Inc., a biotechnology company, where he was responsible for the general supervision of the company's clinical and medical affairs. Prior to this Dr. Kim served in senior leadership roles at Orexigen, EnteroMedics and Amylin Pharmaceutical. He received his medical degree from The Chicago School of Medicine, completed his internal medicine residency at Rush University Medical College, and specialty fellowship training in endocrinology/metabolism at University of California, San Diego UCSD Medical Center. He also holds a M.B.A. with emphasis in biotechnology structure and strategy from UCSD Rady School of Business.- Dennis KIM自2021年5月起担任我们的首席医疗官。从2020年11月至2021年3月，他担任局部药物输送公司Afyx Therapeutics的首席医疗官，在那里他领导了Rivelin的临床，医学和法规开发，Rivelin是一种新型黏膜粘合剂贴片，用于治疗口腔扁平苔藓等疾病。在此之前，从2019年3月至2020年11月，他担任生物技术公司Emerald Health Sciences的首席医疗官，负责公司临床和医疗事务的总体监督，从2011年9月至2019年2月，他担任生物技术公司Zafgen，Inc.的首席医疗官，负责公司临床和医疗事务的总体监督。在此之前，KIM博士在Orexigen，Enteromedics和Amylin Pharmaceutical担任高级领导职务。他获得了芝加哥医学院的医学学位，在拉什大学医学院完成了内科住院医师，并在加州大学圣地亚哥分校医学中心完成了内分泌学/新陈代谢的专业研究金培训。他还拥有UCSD Rady商学院的工商管理硕士学位，重点是生物技术结构和战略。
- Dennis Kim has served as our Chief Medical Officer since May 2021. From November 2020 to March 2021 he served as Chief Medical Officer of Afyx Therapeutics, a topical drug delivery company, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus. Prior to this, from March 2019 to November 2020 he served as Chief Medical Officer of Emerald Health Sciences, a biotechnology company, where he was responsible for the general supervision of the company's clinical and medical affairs, and from September 2011 to February 2019 was Chief Medical Officer at Zafgen, Inc., a biotechnology company, where he was responsible for the general supervision of the company's clinical and medical affairs. Prior to this Dr. Kim served in senior leadership roles at Orexigen, EnteroMedics and Amylin Pharmaceutical. He received his medical degree from The Chicago School of Medicine, completed his internal medicine residency at Rush University Medical College, and specialty fellowship training in endocrinology/metabolism at University of California, San Diego UCSD Medical Center. He also holds a M.B.A. with emphasis in biotechnology structure and strategy from UCSD Rady School of Business.
- Lewis Stuart
Lewis Stuart自2021年5月起担任我们的首席商务官。从2019年12月至2021年5月，Stuart先生担任生物制药公司Myovant Sciences的副总裁兼前列腺癌特许经营负责人。在这个职位上，他领导了公司的前列腺癌启动准备跨功能团队，包括商业，医疗，法律和制造功能。从2013年到2017年，Stuart先生担任医疗保健公司Genomic Health的美国肿瘤特许经营副总裁，负责公司肿瘤业务的各个商业方面。在加入Genomic Health之前，Stuart先生在几家领先的生物制药公司担任高级领导职务，包括Genomic Health和CV Therapeutics。他在Virginia Polytechnic&State University获得通信和营销管理学士学位，并在Northeastern University进行研究生学习。
Lewis Stuart has served as our Chief Commercial Officer since May 2021. From December 2019 to May 2021 Mr. Stuart served as Vice President and Prostate Cancer Franchise Leader for Myovant Sciences, a biopharmaceutical company. In this role he led the company's Prostate Cancer Launch Readiness cross functional team of commercial, medical, legal, and manufacturing functions. From 2013 to 2017 Mr. Stuart served as Vice President, US Oncology Franchise at Genomic Health, a healthcare company, in which role he was responsible for various commercial aspects of the company's oncology business. Prior to Genomic Health, Mr. Stuart held senior leadership roles at several leading biopharmaceutical companies including Genomic Health and CV Therapeutics. He received a B.A. in Communications and Marketing Management from Virginia Polytechnic & State University, with graduate studies at Northeastern University.- Lewis Stuart自2021年5月起担任我们的首席商务官。从2019年12月至2021年5月，Stuart先生担任生物制药公司Myovant Sciences的副总裁兼前列腺癌特许经营负责人。在这个职位上，他领导了公司的前列腺癌启动准备跨功能团队，包括商业，医疗，法律和制造功能。从2013年到2017年，Stuart先生担任医疗保健公司Genomic Health的美国肿瘤特许经营副总裁，负责公司肿瘤业务的各个商业方面。在加入Genomic Health之前，Stuart先生在几家领先的生物制药公司担任高级领导职务，包括Genomic Health和CV Therapeutics。他在Virginia Polytechnic&State University获得通信和营销管理学士学位，并在Northeastern University进行研究生学习。
- Lewis Stuart has served as our Chief Commercial Officer since May 2021. From December 2019 to May 2021 Mr. Stuart served as Vice President and Prostate Cancer Franchise Leader for Myovant Sciences, a biopharmaceutical company. In this role he led the company's Prostate Cancer Launch Readiness cross functional team of commercial, medical, legal, and manufacturing functions. From 2013 to 2017 Mr. Stuart served as Vice President, US Oncology Franchise at Genomic Health, a healthcare company, in which role he was responsible for various commercial aspects of the company's oncology business. Prior to Genomic Health, Mr. Stuart held senior leadership roles at several leading biopharmaceutical companies including Genomic Health and CV Therapeutics. He received a B.A. in Communications and Marketing Management from Virginia Polytechnic & State University, with graduate studies at Northeastern University.
- Paul T. Quinlan
Paul T. Quinlan，2010年起，担任本公司法律总顾问、企业秘书。2005-2010，他在生物制药公司Metabolex担任法律总顾问，负责法律事务。2000-2005，他在生物制药公司Maxygen的法律部门担任过各种职务，最后的是公司证券首席法律顾问。加入Maxygen之前，他是律师事务所Cooley LLP和Cravath, Swaine & Moore LLP的律师。他在Columbia University Law School获得法律学位，在University of Toronto获得医学生物物理硕士学位。
Paul T. Quinlan has served as our General Counsel and Corporate Secretary since 2010 and our Chief Legal Officer since 2016. From 2005 to 2010 Mr. Quinlan was General Counsel at Metabolex, Inc., a biopharmaceutical company. In this position, he was responsible for overseeing the legal affairs of Metabolex, Inc. From 2000 to 2005 Mr. Quinlan held various positions in the legal department at Maxygen, Inc., a biopharmaceutical company, most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Inc., Mr. Quinlan was an associate at Cooley LLP, a law firm, and Cravath, Swaine & Moore LLP, a law firm. Mr. Quinlan obtained a law degree from Columbia University Law School and a M.Sc. in Medical Biophysics from the University of Toronto.- Paul T. Quinlan，2010年起，担任本公司法律总顾问、企业秘书。2005-2010，他在生物制药公司Metabolex担任法律总顾问，负责法律事务。2000-2005，他在生物制药公司Maxygen的法律部门担任过各种职务，最后的是公司证券首席法律顾问。加入Maxygen之前，他是律师事务所Cooley LLP和Cravath, Swaine & Moore LLP的律师。他在Columbia University Law School获得法律学位，在University of Toronto获得医学生物物理硕士学位。
- Paul T. Quinlan has served as our General Counsel and Corporate Secretary since 2010 and our Chief Legal Officer since 2016. From 2005 to 2010 Mr. Quinlan was General Counsel at Metabolex, Inc., a biopharmaceutical company. In this position, he was responsible for overseeing the legal affairs of Metabolex, Inc. From 2000 to 2005 Mr. Quinlan held various positions in the legal department at Maxygen, Inc., a biopharmaceutical company, most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Inc., Mr. Quinlan was an associate at Cooley LLP, a law firm, and Cravath, Swaine & Moore LLP, a law firm. Mr. Quinlan obtained a law degree from Columbia University Law School and a M.Sc. in Medical Biophysics from the University of Toronto.
- Sujal Shah
Sujal Shah于2013年12月加入CymaBay，担任财务总监。在此之前，自2012年6月以来曾担任顾问和代理首席财务官。自2010年至2012年担任花旗集团卫生保健投资银行业务的主任，负责管理客户关系，并执行战略和融资相关交易，为专注于生命科学领域的客户服务。从2004年至2010年受雇于Credit-Suisse，最后担任医疗保健投资银行集团的副总裁。2004年在卡耐基梅隆大学泰珀商学院收到了工商管理硕士学位，1997年在美国西北大学获得生物医学工程学士学位。
Sujal Shah has served as our President and Chief Executive Officer since November 2017. Prior to that he served as our Interim President and Chief Executive Officer from March 2017 to November 2017. From December 2013 to March 2017 Mr. Shah served as Chief Financial Officer. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012 Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Directors of Tvardi Therapeutics, Inc. and the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received an M.B.A. from Carnegie Mellon University-Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.- Sujal Shah于2013年12月加入CymaBay，担任财务总监。在此之前，自2012年6月以来曾担任顾问和代理首席财务官。自2010年至2012年担任花旗集团卫生保健投资银行业务的主任，负责管理客户关系，并执行战略和融资相关交易，为专注于生命科学领域的客户服务。从2004年至2010年受雇于Credit-Suisse，最后担任医疗保健投资银行集团的副总裁。2004年在卡耐基梅隆大学泰珀商学院收到了工商管理硕士学位，1997年在美国西北大学获得生物医学工程学士学位。
- Sujal Shah has served as our President and Chief Executive Officer since November 2017. Prior to that he served as our Interim President and Chief Executive Officer from March 2017 to November 2017. From December 2013 to March 2017 Mr. Shah served as Chief Financial Officer. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012 Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Directors of Tvardi Therapeutics, Inc. and the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received an M.B.A. from Carnegie Mellon University-Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.
- Charles A. McWherter
Charles A. McWherter，博士，自2007年7月起担任本公司的高级副总裁兼首席科学官。从2003年到2007年，他担任辉瑞公司（一家生物制药公司）的副总裁和心血管治疗领域的负责人。从2001年至2003年在Sugen公司（于2003年被辉瑞公司收购的一家生物制药公司）担任药物开发的副总裁。从康奈尔大学获得博士学位。
Charles A. McWherter has served as our Chief Scientific Officer since 2013. From 2007 to 2013 he served as our Senior Vice President, Research and Preclinical Development. From 2003 to 2007 he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc., a biopharmaceutical company. From 2001 to 2003 Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a biopharmaceutical company acquired by Pfizer Inc. in 2003. Dr. McWherter obtained his Ph.D. from Cornell University.- Charles A. McWherter，博士，自2007年7月起担任本公司的高级副总裁兼首席科学官。从2003年到2007年，他担任辉瑞公司（一家生物制药公司）的副总裁和心血管治疗领域的负责人。从2001年至2003年在Sugen公司（于2003年被辉瑞公司收购的一家生物制药公司）担任药物开发的副总裁。从康奈尔大学获得博士学位。
- Charles A. McWherter has served as our Chief Scientific Officer since 2013. From 2007 to 2013 he served as our Senior Vice President, Research and Preclinical Development. From 2003 to 2007 he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc., a biopharmaceutical company. From 2001 to 2003 Dr. McWherter served as Vice President of Drug Discovery at Sugen, Inc., a biopharmaceutical company acquired by Pfizer Inc. in 2003. Dr. McWherter obtained his Ph.D. from Cornell University.
- Kurt von Emster
Kurt von Emster，终审法院，自2009年4月起担任董事。由于他对医药行业的深入了解和他对MPM BioEquities Master Fund LP的投资，被选为董事会成员。他是venBio LLC的创办人之一和管理合伙人。23年来一直担任生物技术和医疗保健分析师和投资组合经理。他是Aurinia制药公司和Cytos Biotechnology AG的董事，曾任Facet Biotech公司（在2010年出售给雅培公司）和SOMAXON制药公司（在2013年卖给Pernix治疗控股有限公司）的董事会前成员，和Acceleron制药公司的前董事会观察员。他的投资生涯开始于1989年在富兰克林邓普顿的投资，在20世纪90年代创立并管理各种健康和生物技术基金会，每个基金会实现一个5星级的晨星排名。 2000年，他为Franklin Templeton管理超过20亿美元的生物技术和医疗保健基金。 2001年，他成为MPM Capital（一家领先的生物技术私募股权公司）的普通合伙人，并推出了MPM BioEquities基金（一个跨越公共和私营生物技术的对冲基金）。从2001年成立直到2009年离开，他是这个基金的投资组合经理。在MPM的任职期间，他还与他人共同创办了MPM Biogen Idec公司战略基金。他在venBio的旧金山办公室工作。
Kurt von Emster has served on our board of directors since October 2020. Mr. von Emster currently serves as Managing Partner at Abingworth LLP, a venture capital firm, where he has been employed as a Partner since January 2015. Mr. von Emster has served as a member of the board of directors of Tizona Therapeutics, Inc, a biotechnology company, since December 2020 Trishula Therapeutics, Inc., an immunotherapy company, since December 2020 Orbus Therapeutics, Inc., a pharmaceutical company, since July 2020 SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since April 2020 Jasper Therapeutics, Inc., a biotechnology company, since November 2019 Vaxcyte Inc. Vaxcyte, a biopharmaceutical vaccine company, since July 2015 and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr. von Emster previously served on the board of directors of the following companies: CRISPR Therapeutics, Inc. from March 2015 to June 2019 Kesios Therapeutics Ltd. from November 2015 to January 2017 Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros Biosciences AG in January 2016), Aurinia Pharmaceuticals Inc. from February 2014 to March 2015 Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from February 2009 to April 2010 and Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics Holdings, Inc. in March 2013) from August 2005 to March 2013. In addition, Mr. von Emster co-founded venBio LLC, a health-care focused investment firm, in 2009 and served as Partner until 2014. Prior to that, Mr. von Emster was General Partner at MPM Capital, Inc., a biotechnology private equity firm, from 2000 to 2009. Mr. von Emster was also a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton Group from 1989 to 2000. Mr. von Emster received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (C.F.A.).- Kurt von Emster，终审法院，自2009年4月起担任董事。由于他对医药行业的深入了解和他对MPM BioEquities Master Fund LP的投资，被选为董事会成员。他是venBio LLC的创办人之一和管理合伙人。23年来一直担任生物技术和医疗保健分析师和投资组合经理。他是Aurinia制药公司和Cytos Biotechnology AG的董事，曾任Facet Biotech公司（在2010年出售给雅培公司）和SOMAXON制药公司（在2013年卖给Pernix治疗控股有限公司）的董事会前成员，和Acceleron制药公司的前董事会观察员。他的投资生涯开始于1989年在富兰克林邓普顿的投资，在20世纪90年代创立并管理各种健康和生物技术基金会，每个基金会实现一个5星级的晨星排名。 2000年，他为Franklin Templeton管理超过20亿美元的生物技术和医疗保健基金。 2001年，他成为MPM Capital（一家领先的生物技术私募股权公司）的普通合伙人，并推出了MPM BioEquities基金（一个跨越公共和私营生物技术的对冲基金）。从2001年成立直到2009年离开，他是这个基金的投资组合经理。在MPM的任职期间，他还与他人共同创办了MPM Biogen Idec公司战略基金。他在venBio的旧金山办公室工作。
- Kurt von Emster has served on our board of directors since October 2020. Mr. von Emster currently serves as Managing Partner at Abingworth LLP, a venture capital firm, where he has been employed as a Partner since January 2015. Mr. von Emster has served as a member of the board of directors of Tizona Therapeutics, Inc, a biotechnology company, since December 2020 Trishula Therapeutics, Inc., an immunotherapy company, since December 2020 Orbus Therapeutics, Inc., a pharmaceutical company, since July 2020 SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since April 2020 Jasper Therapeutics, Inc., a biotechnology company, since November 2019 Vaxcyte Inc. Vaxcyte, a biopharmaceutical vaccine company, since July 2015 and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr. von Emster previously served on the board of directors of the following companies: CRISPR Therapeutics, Inc. from March 2015 to June 2019 Kesios Therapeutics Ltd. from November 2015 to January 2017 Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros Biosciences AG in January 2016), Aurinia Pharmaceuticals Inc. from February 2014 to March 2015 Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from February 2009 to April 2010 and Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics Holdings, Inc. in March 2013) from August 2005 to March 2013. In addition, Mr. von Emster co-founded venBio LLC, a health-care focused investment firm, in 2009 and served as Partner until 2014. Prior to that, Mr. von Emster was General Partner at MPM Capital, Inc., a biotechnology private equity firm, from 2000 to 2009. Mr. von Emster was also a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton Group from 1989 to 2000. Mr. von Emster received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (C.F.A.).